# Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

> **NCT06361940** · PHASE2 · RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Aromatase inhibitors or tamoxifen

## Key facts

- **NCT ID:** NCT06361940
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06361940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06361940, "Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06361940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*